MetLife (United States) (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
67
Publications
1397
Citations
40538
i10-index
330
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
2021 ESC Guidelines for the diagnosis and treatmen... | 2021 | 12039 |
Cardiac Hypertrophy: The Good, the Bad, and the Ug... | 2003 | 1442 |
Mavacamten for treatment of symptomatic obstructiv... | 2020 | 1097 |
Hypertrophy of the Heart | 2004 | 861 |
CaM kinase signaling induces cardiac hypertrophy a... | 2000 | 518 |
Activation of Cardiac Fibroblast Growth Factor Rec... | 2015 | 514 |
Left Ventricular Unloading Is Associated With Lowe... | 2020 | 483 |
Activated glycogen synthase-3β suppresses cardiac ... | 2002 | 476 |
Longitudinal Multi-omics Analyses Identify Respons... | 2020 | 400 |
Independent Signals Control Expression of the Calc... | 2000 | 354 |
Norbert Frey is a researcher with 1397 publications and 40538 citations. They are affiliated with MetLife (United States). Their research focuses on . With an h-index of 67, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Norbert Frey and 250M+ other papers.
Citations per publication by year